GRFS (Grifols) ROE % Adjusted to Book Value: 6.22% (As of Mar. 2026)


GRFS Grifols SA GRFS
84 GF Score
Price $7.36
GF Value $8.79
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Grifols ROE % Adjusted to Book Value?

Grifols GRFS +2.08% 84 ROE % Adjusted to Book Value is 6.22% as of Mar. 2026. GuruFocus rates GRFS with a GF Score™ of 84/100 and a GF Value™ of $8.79 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Grifols's ROE % for the quarter that ended in Mar. 2026 was 5.41%. Grifols's PB Ratio for the quarter that ended in Mar. 2026 was 0.87. Grifols's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 6.22%.

Grifols ROE % Adjusted to Book Value Related Terms

Grifols ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Grifols's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols ROE % Adjusted to Book Value Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.80 3.34 0.57 3.34 7.41

Grifols Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 8.80 8.84 7.29 6.22

GRFS vs LLY, JNJ, ABBV: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - General subindustry, Grifols's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grifols ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Grifols's ROE % Adjusted to Book Value falls into.


GRFS
84GF Score
Grifols SA GRFS
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grifols ROE % Adjusted to Book Value Calculation

Grifols's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=7.63% / 1.03
=7.41%

Grifols's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=5.41% / 0.87
=6.22%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 6.22% mean?
Grifols (GRFS) has a ROE % Adjusted to Book Value of 6.22% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Grifols and its competitors.
Is Grifols' ROE % Adjusted to Book Value too high?
Grifols' current ROE % Adjusted to Book Value is 6.22%. Overall, Grifols has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' ROE % Adjusted to Book Value compare to LLY and JNJ?
Grifols' ROE % Adjusted to Book Value of 6.22% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Grifols and its competitors. Grifols's current ROE % Adjusted to Book Value is 6.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.79, compared to a current price of $7.36 — trading 16.3% below its estimated fair value. The current ROE % Adjusted to Book Value is 6.22%. Grifols' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Grifols (GRFS), the current ROE % Adjusted to Book Value is 6.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (GRFS) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of $7.36 is trading 16.3% below its estimated GF Value™ of $8.79. GuruFocus considers Grifols to be Modestly Undervalued.

Key valuation signals for GRFS:

  • ROE % Adjusted to Book Value: 6.22%
  • GF Value™: $8.79 vs. price of $7.36 (16.3% below fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score

Get the complete analysis for GRFS

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.36
Price
$8.79
GF Value